Neoadjuvant Treatment
Mostrando 1-12 de 51 artigos, teses e dissertações.
-
1. Effects of enhancer of zeste homolog 2 and mucin 1 expressions on treatment response in breast cancer
SUMMARY OBJECTIVE: Breast cancer is the most common malignancy in women. In the treatment of these patients, pathological complete response is defined as the absence of invasive cancer in breast or lymph node tissue after the completion of neoadjuvant chemotherapy. In this study, we aimed to investigate the relationship of enhancer of zeste homolog 2 and mu
Revista da Associação Médica Brasileira. Publicado em: 2023
-
2. The effect of positron emission tomography/computed tomography in axillary surgery approach after neoadjuvant treatment in breast cancer
SUMMARY OBJECTIVE: The aim of this study was to determine the role of positron emission tomography/computed tomography in the decision to perform axillary surgery by comparing positron emission tomography/computed tomography findings with pathology consistency after neoadjuvant chemotherapy. METHODS: Patients who were diagnosed for T1-4, cN1/2 breast cance
Revista da Associação Médica Brasileira. Publicado em: 2023
-
3. Watch and Wait, Worth It?
Abstract Background The surgery with total mesorectal excision recommended by R. J. Heald in 1982 is the gold standard. Rectal cancer (RC) surgery has a morbidity rate ranging from 6 to 35%, and it can cause functional issues such as sexual, urinary, and bowel dysfunction in the long term. Neoadjuvant chemoradiotherapy (CRT) has been gaining ground in patie
Journal of Coloproctology (Rio de Janeiro). Publicado em: 2022
-
4. Factors associated with utilization of neoadjuvant chemotherapy in charlson comorbidity zero non-metastatic muscle-invasive bladder cancer patients
ABSTRACT Background: Guideline-based best practice treatment for muscle invasive bladder cancer (MIBC) involves neoadjuvant chemotherapy followed by radical cystectomy (NACRC). Prior studies have shown that a minority of patients receive NACRC and older age and renal function are drivers of non-receipt of NACRC. This study investigates treatment rates and f
Int. braz j urol.. Publicado em: 2021-08
-
5. Editorial Comment: Parasacral transcutaneous electrical nerve stimulation in children with overactive bladder: comparison between sessions administered two and three times weekly
ABSTRACT Background: Guideline-based best practice treatment for muscle invasive bladder cancer (MIBC) involves neoadjuvant chemotherapy followed by radical cystectomy (NACRC). Prior studies have shown that a minority of patients receive NACRC and older age and renal function are drivers of non-receipt of NACRC. This study investigates treatment rates and f
Int. braz j urol.. Publicado em: 2021-08
-
6. Integrated care pathway for rectal cancer treatment: cross-sectional post-implementation study using a logic model framework
ABSTRACT BACKGROUND: Management of rectal cancer has become more complex with multimodality therapy (neoadjuvant chemoradiotherapy and surgery) and this has led to the need to organize multidisciplinary teams. The aim of this study was to report on the planning, implementation and evaluation of an integrated care pathway for neoadjuvant treatment of middle
Sao Paulo Med. J.. Publicado em: 13/01/2020
-
7. TRANSHIATAL ESOPHAGECTOMY IS NOT ASSOCIATED WITH POOR QUALITY LYMPHADENECTOMY
RESUMO Racional: No câncer esofágico a terapia neoadjuvante seguida de procedimento cirúrgico aumenta a probabilidade de sucesso do tratamento. Objetivo: Avaliar variáveis que podem influenciar o número de linfonodos recuperados, o número de linfonodos metastáticos recuperados e a recorrência linfonodal na esofagectomia após quimiorradioterapia ne
ABCD, arq. bras. cir. dig.. Publicado em: 20/12/2019
-
8. PANCREATODUODENECTOMY FOR SOLID PSEUDOPAPILLARY TUMOR OF THE PANCREAS: A MULTI-INSTITUTION STUDY
RESUMO Racional: Tumor sólido pseudopapilar do pâncreas é neoplasia maligna rara, de baixo grau de malignidade. A maioria dos pacientes apresenta sintomas inespecíficos até que o tumor aumente de tamanho. A ressecção cirúrgica completa através a duodenopancreatectomia é o tratamento de escolha para os localizados na cabeça do pâncreas. Objeti
ABCD, arq. bras. cir. dig.. Publicado em: 26/08/2019
-
9. Timing of neoadjuvant therapy and surgical treatment in rectal cancer
RESUMO Objetivos do estudo: Avaliar o timing ideal entre a terapêutica neoadjuvante e cirúrgica no carcinoma do reto e a sua influência nos outcomes de tratamento. Material e métodos: Utilizando a “PubMed”, foi feita uma revisão sistemática da literatura disponível acerca da influência do timing cirúrgico após quimiorradioterapia neoadjuvante
J. Coloproctol. (Rio J.). Publicado em: 13/06/2019
-
10. Assessment of the non-surgical treatment of patients with rectal cancer who underwent neoadjuvant treatment with chemotherapy and radiotherapy at the oncology department
RESUMO Objetivo: Descrever os resultados parciais de estudo em pacientes com câncer de reto submetidos a tratamento neoadjuvante com quimioterapia e radioterapia quanto à taxa resposta clínica completa, sobrevida livre de doença, função anorretal e qualidade de vida. Material e métodos: Estudo prospectivo desde junho 2015 até junho de 2018, em paci
J. Coloproctol. (Rio J.). Publicado em: 13/06/2019
-
11. CONVERSION THERAPY FOR GASTRIC CANCER: EXPANDING THE TREATMENT POSSIBILITIES
RESUMO Racional : A terapia de conversão no câncer gástrico (CG) é definida como o uso de quimio/radioterapia seguida de ressecção cirúrgica com intenção curativa de um tumor que era considerado irressecável ou oncologicamente incurável. Objetivo : Avaliar os resultados da terapia de conversão no tratamento do CG. Métodos : Análise ret
ABCD, arq. bras. cir. dig.. Publicado em: 29/04/2019
-
12. Fatores prognósticos de resposta à quimioterapia em tumores avançados do colo uterino: o papel da neoangiogênese.
RESUMO Objetivo: analisar a expressão do Fator de Crescimento do Endotélio Vascular (VEGF), seu receptor (VEGFR-2), idade e tipo histológico de carcinomas avançados de colo uterino com relação à resposta clínica à quimioterapia neoadjuvante. Métodos: foram incluídas 40 pacientes com diagnóstico de carcinoma de colo uterino (IB2 e IVA), com bió
Rev. Col. Bras. Cir.. Publicado em: 18/02/2019